Histogen is a regenerative medicine company focused on developing patented, innovative technologies for aesthetic and therapeutic markets that replace and regenerate tissues in the body. The Company currently has three product candidates in clinical development intended to address what Histogen believes to be underserved, multi-billion dollar global markets: a treatment for hair loss, a dermal filler and a treatment for joint cartilage repair.

History

Histogen, Inc., a Delaware Corporation, was founded in 2007. The Company is focused on developing innovative products based upon Histogen’s unique technology that utilizes the proteins and growth factors produced by cells grown under simulated embryonic conditions. The Company is headquartered in San Diego, California.

Histogen founder Dr. Gail Naughton is a highly respected scientist with extensive experience in the field of tissue engineering and regenerative medicine. Dr. Naughton discovered the potential of proteins and growth factors produced by hypoxia-induced multipotent cells for therapeutic and biomedical applications, and developed Histogen’s unique technology process to create products based on these proteins. The technology is protected by patent families filed in the US and across key geographies.

Our Mission

To redefine regenerative medicine by developing high value therapeutic and aesthetic products that stimulate the body’s own stem cells to regenerate tissues, without the use of embryonic stem cells or animal components.

Histogen’s executive management team has decades of experience in bringing cell-based regenerative products from concept to market. In addition, the Company’s Board of Directors and scientific advisors are leaders in the fields of regenerative medicine and global marketing and business operations. Histogen has brought on experienced consultants to advise the team in regulatory, quality and production areas.

Richard Pascoe

Richard W. Pascoe has been a director and served as Chairman and Chief Executive Officer of Histogen Incorporated since January of 2019.

Know More

Gail K. Naughton, Ph.D.

Dr. Naughton founded Histogen, Inc. in 2007, and currently serves as Chief Scientific Officer for the Company.

Know More

Martin Latterich, Ph.D.

Dr. Latterich is a biotechnology executive with a strong mix of business and academic experience.

Know More

Thomas Hubka

Thomas has spent 9 years with Histogen focusing on business development, finance.

Know More

Michael P. Zimber, Ph.D.

Dr. Michael Zimber brings to Histogen over 25 years of diverse experience in the biotechnology.

Know More

Dr. Mark A. Hubka

Dr. Hubka brings more than 25 years of clinical experience from the fields of orthopedics and sports medicine.

Know More

Eileen Brandt

Eileen has spent more than 13 years in communications, with a focus on public relations.

Know More

Stephen Chang

In addition to Histogen, Dr. Stephen Chang serves on the Scientific Advisory Board or Board of Directors for GT Biopharma and Orphesus Therapeutics, Cloak Therapeutics, Aegis Therapeutics and Legacy Therapeutics.

Know More

Richard Pascoe

Richard W. Pascoe has been a director and served as Chairman and Chief Executive Officer of Histogen Incorporated since January of 2019.

Know More

Yizhuo Zhang

Yizhuo Zhang is currently the director of Strategy and Investment Department of Huapont Life Sciences where he is in charge of all aspects of the group investment activities.

Know More

David H. Crean

David H. Crean, Ph.D is a Managing Director at Objective Capital Partners where he leads the firm’s life science investment banking transactions and 20 years of life sciences R&D and corporate development.

Know More

Jonathan Jackson

A few years after completing his degree in Business Management in London, Jonathan Jackson set up his own company to develop commercial real estate in Central Europe.

Know More

Brian Satz

Brian M. Satz is an attorney and founder of Satz Law Group LLC in Fairfield, New Jersey. Mr. Satz has extensive experience representing clients in all aspects of corporate and commercial.

Know More